-
CF: Vertex, Ireland Reach Agreement for Reimbursement of Triple Combo
People with cystic fibrosis in Ireland may be among the first in Europe to access Vertex Pharmaceuticals’ regimen of elexacaftor, tezacaftor, and Kalydeco. Read more here.
How do you feel about this news?
Sorry, there were no replies found.
Log in to reply.